<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05012189</url>
  </required_header>
  <id_info>
    <org_study_id>INSI-202107</org_study_id>
    <nct_id>NCT05012189</nct_id>
  </id_info>
  <brief_title>Baloxavir Versus Oseltamivir for Nursing Home Influenza Outbreaks</brief_title>
  <official_title>Comparative Effectiveness of Baloxavir Versus Oseltamivir for Influenza Outbreak Management in U.S. Nursing Homes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Insight Therapeutics, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Case Western Reserve University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Insight Therapeutics, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Influenza outbreaks are a prevalent event in nursing homes (NHs). We will study baloxavir&#xD;
      compared to oseltamivir when used for influenza prophylaxis when facilities identify an index&#xD;
      incident case of influenza. This study will help guide nursing home's decision making and&#xD;
      demonstrate the effectiveness of a novel antiviral for preventing influenza outbreaks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A random study sample of about 1000 U.S. nursing homes (NHs), housing approximately 112,000&#xD;
      overall residents and 92,000 over the age of 65 years, of whom 64,500 are long-stay NH&#xD;
      residents, will be recruited for the study. Participating facilities will be randomly&#xD;
      allocated in a 1:1 ratio to oseltamivir or baloxavir for antiviral treatment and prophylaxis.&#xD;
      Primary study data provided by facilities monthly during the influenza season will support&#xD;
      primary and secondary endpoints along with administrative claims and public use datasets&#xD;
      containing information on facility characteristics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Pragmatic Cluster Randomized Clinical Trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total number of ILI cases defined, following the index influenza case identification in nursing homes randomized to baloxavir or oseltamivir</measure>
    <time_frame>Up to 8 months each influenza season</time_frame>
    <description>To demonstrate the non-inferiority of prophylactic baloxavir vs. oseltamivir to prevent influenza-like illness (ILI) after an index influenza case in nursing homes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Outbreak duration defined as the time of the first laboratory-confirmed case of influenza to 7 days following the last identified case of influenza-like illness requiring treatment with baloxavir or oseltamivir</measure>
    <time_frame>Up to 8 months each influenza season</time_frame>
    <description>To determine the difference in total outbreak duration for each outbreak occurring in nursing homes randomized to offer either single-dose baloxavir or oseltamivir for outbreak abatement during the 2021-2022 influenza season.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Facility-level data on antiviral courses of treatment administered from Medication Administration Records</measure>
    <time_frame>Up to 8 months each influenza season</time_frame>
    <description>To determine the difference in number of courses of treatment of baloxavir or oseltamivir needed for outbreak control in nursing homes randomized to baloxavir or oseltamivir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations from Minimum Data Set (MDS) 3.0 (interim) and Medicare A claims</measure>
    <time_frame>Up to 8 months each influenza season</time_frame>
    <description>To determine the difference in respiratory-related hospitalization rates during the 2021-2022 influenza season experienced by long-stay nursing home residents 65 and older living in nursing homes randomized to either baloxavir or oseltamivir.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality from Medicare Vital Status File</measure>
    <time_frame>Up to 8 months each influenza season</time_frame>
    <description>To determine the differences in long-stay residents' mortality rates in nursing homes randomized to either baloxavir or oseltamivir.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Influenza</condition>
  <condition>Influenza, Human</condition>
  <condition>Influenza -Like Illness</condition>
  <arm_group>
    <arm_group_label>Oseltamivir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nursing homes randomized to receive oseltamivir for treatment and chemoprophylaxis for influenza.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baloxavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nursing homes randomized to receive baloxavir for treatment and chemoprophylaxis for influenza.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir</intervention_name>
    <description>Nursing home residents and staff 18 years and older are allocated to receive oseltamivir for treatment and chemoprophylaxis for influenza.</description>
    <arm_group_label>Oseltamivir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baloxavir</intervention_name>
    <description>Nursing home residents and staff 18 years and older are allocated to receive baloxavir for treatment and chemoprophylaxis for influenza.</description>
    <arm_group_label>Baloxavir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Medicare-certified NHs in any location in the United States with at least 50 long-stay&#xD;
             residents 18 years of age or older.&#xD;
&#xD;
          -  Facilities with at least 80% of their long-stay population 65 years of age or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hospital-based facilities&#xD;
&#xD;
          -  Facilities not submitting MDS data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>H E Davidson, PharmD, MPH</last_name>
    <phone>7576256040</phone>
    <email>edavidson@inther.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa F Han, MPH</last_name>
    <phone>7576256040</phone>
    <email>Lhan@inther.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Insight Therapeutics, LLC</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H E Davidson, PharmD, MPH</last_name>
      <phone>757-625-6040</phone>
      <email>Edavidson@Inther.com</email>
    </contact>
    <contact_backup>
      <last_name>Lisa F Han, MPH</last_name>
      <phone>7576256040</phone>
      <email>LHan@inther.com</email>
    </contact_backup>
    <investigator>
      <last_name>H E Davidson, PharmD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Gravenstein, MD, MPH, MA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 12, 2021</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antiviral Medication</keyword>
  <keyword>Influenza</keyword>
  <keyword>Nursing Home</keyword>
  <keyword>Influenza Outbreak</keyword>
  <keyword>Outbreak</keyword>
  <keyword>Oseltamivir</keyword>
  <keyword>Baloxavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oseltamivir</mesh_term>
    <mesh_term>Baloxavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

